Navigation Links
WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering
Date:1/20/2012

LOS ANGELES, Jan. 20, 2012 /PRNewswire/ -- WestPark Capital, Inc. announced the initial closing of a private placement for Arrogene NanoTechnology, Inc. on January 10, 2012.  A total of 500,000 Units, each Unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds of approximately $500,000.  Proceeds from the offering will be used for working capital and research and development related to Arrogene's diagnostic and therapeutic technologies for brain, breast and lung cancer.  WestPark Capital, Inc. acted as placement agent for the offering.

This news release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful.  The offering was made only by Confidential Private Placement Memorandum.  Copies of the Confidential Private Placement Memorandum may be obtained via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

About WestPark Capital, Inc.

WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide.  WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them.  WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services.  Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at info@wpcapital.com. Member: FINRA/SIPC

About Arrogene NanoTechnology, Inc.

Arrogene NanoTechnology is developing a new generation of diagnostic and therapeutic drugs based on a new family of nano-biopolymers.  Arrogene was founded in 2007 to commercialize a new cancer targeting technology and a proprietary molecular delivery platform that interferes with cancer targets to inhibit and finally eradicate tumor progression.  Additional information about Arrogene is available at www.arrogene.com.

Contact:
WestPark Capital, Inc.
Richard Rappaport, CEO
(310) 843-9300

 


'/>"/>
SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WestPark Capital Announces $2.6 Million IsoRay Offering
2. WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
3. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Global ... competitive market to drive long-term market growth ... common set of chronic disorders that affect 5–7% ... in terms of their symptoms and key patient ... dysregulation of immune pathways and an inappropriate immune ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online for ... 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, ... interventions and causes of chronic illness in children. , Very recent articles have cited ...
(Date:2/7/2016)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... ability to correct pelvic organ prolapse with the latest techniques and the most ... greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors include ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):